Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects

Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2015-10, Vol.90 (1), p.1-7
Hauptverfasser:	Chuang, Jody C, Neal, Joel W, Niu, Xiao-Min, Wakelee, Heather A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant Anaplastic lymphoma kinase (ALK) Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Adjuvant Epidermal growth factor receptor (EGFR) Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Non-small cell lung cancer (NSCLC) Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Randomized Controlled Trials as Topic Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Tyrosine kinase inhibitors (TKI)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • TKIs against targetable mutations are highly effective in the metastatic setting. • There is much interest in the role of TKIs in the adjuvant setting to improve survival rate. • The use of TKIs in the adjuvant setting remains experimental and controversial. • Many trials involving TKIs in the adjuvant settings are ongoing worldwide.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2015.07.016